Guardant Health Inc (NAS:GH)
$ 29.54 0 (0%) Market Cap: 3.61 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 52.66 GF Score: 70/100

Guardant Health Inc at Cowen Health Care Conference Transcript

Mar 13, 2019 / 12:00PM GMT
Release Date Price: $94.45 (+27.64%)
Doug Schenkel
Cowen and Company - Analyst

All right. Good morning, everyone, and welcome to day three of the Cowen Health Care Conference. For those of you who don't know me, I'm Doug Schenkel. I'm one of the healthcare analysts here at Cowen.

It's my pleasure to welcome you to this morning's presentation with Guardant Health. Guardant Health is the clear leader in liquid biopsy testing. The Company has done a fantastic job of amassing a very robust clinical dossier that has really led to a lot of success, both on the clinical side and also with a series of biopharmaceutical partners.

This is a very exciting year; the Company continues to make progress on both fronts. In a few weeks, we expect a lot of new data and catalysts at the AACR conference. Later this year, we have a series of expected clinical and regulatory catalysts, so there's lots to talk about, lots of excitement. And this is all coming off of a nice quarterly update last night.

So, with that all in mind, I'm going to hand it over to the Company's CEO, Helmy, who can tell the story much better than I can. Just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot